Zymeworks Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Zymeworks Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-27.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 63% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 74%
Sales fell 74% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-74% / -47%In 3 years sales changed by -74% while total assets changed by -47%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-9.5×Operating cash was negative last year, while some debt falls due within a year.
Higher than 55% of Healthcare companies in United States.
Cash Cushion Ratio
+10%Cash, after subtracting all debt, equals 10% of its market value (net cash).
Higher than 51% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 77% of Healthcare companies in United States.
Tangible Net Worth Ratio
95%Of every $100 of net worth, $95 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 81% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Zymeworks Inc. made a loss over the last year. Zymeworks Inc. owes $0.80 for every $1 it owns. Zymeworks Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossZymeworks Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
25.19The share price is 25.19 times Zymeworks Inc.'s book value per share, higher than 95% of Healthcare companies in United States.
Market cap
$2.0 BThe total market value of all of Zymeworks Inc.'s shares at today's price (share price × number of shares), larger than 75% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$80 MWhat Zymeworks Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.12Net worth divided by the number of shares. The share price of $28.22 is 25.2 times this, which is the P/B above.
Return on equity (ROE)
-72.3%Zymeworks Inc. lost 72.3% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
Owes vs Owns
0.80×Zymeworks Inc. owes $0.80 for every $1 it owns (moderate), higher than 78% of Healthcare companies in United States.
Dividend yield
NoneZymeworks Inc. does not currently pay a dividend.
Revenue growth
+39%Revenue rose 39% in the year to Dec 2025, and shrank 36% a year on average over 3 years.
Profit growth
LossZymeworks Inc. made a loss in each of the last two years.
Profit margin
-76.6%Zymeworks Inc. lost $77 for every $100 of revenue.
Cash vs debt
Net cashZymeworks Inc. held $211 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Zymeworks Inc.: $2.0 B ÷ $80 M (30 Jun 2026) = 25.2.
What is Zymeworks Inc.'s return on equity?
Zymeworks Inc. lost 72.3% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
How much does Zymeworks Inc. owe compared with what it owns?
Zymeworks Inc. owes $0.80 for every $1 it owns (moderate), higher than 78% of Healthcare companies in United States.
Does Zymeworks Inc. pay a dividend?
No. Zymeworks Inc. does not currently pay a dividend.
Is Zymeworks Inc.'s revenue growing?
Revenue rose 39% in the year to Dec 2025, and shrank 36% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.